Nicotinamide Mononucleotide (NMN) is a precursor to nicotinamide adenine dinucleotide (NAD+), a critical molecule involved in cellular energy metabolism and DNA repair. Recent scientific interest has focused on NMN and other NAD+ boosters as potential interventions for age-related and metabolic diseases, including peripheral neuropathy. Preclinical studies, primarily in animal models, suggest that boosting NAD+ levels via NMN supplementation may have neuroprotective effects. For example, some mouse studies demonstrate that raising NAD+ levels can delay axonal degeneration and support nerve regeneration after injury. These effects are thought to be mediated through improved mitochondrial function, enhanced DNA repair, and activation of sirtuins, which are proteins involved in cellular health and stress resistance.

However, direct clinical evidence for NMN’s efficacy in treating or supporting peripheral neuropathy in humans is lacking. No large, well-controlled human clinical trials have been published as of mid-2024 specifically addressing NMN's effects on peripheral neuropathy. Most evidence remains preclinical, and human data are limited to studies on NAD+ metabolism more broadly. While the scientific rationale is promising and supported by animal models, the current level of evidence is insufficient to recommend NMN as a standard treatment for peripheral neuropathy. Thus, its use is best considered experimental and should be approached with caution until more robust human data are available.